

**MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY
COMMITTEE
Recommendations Summary
November 07, 2012**

In Attendance:

	Committee Member	Yes or No
1	Rosanne Barber	Yes
2	Catherine Decker PharmD	Yes
4	Lawrence Fleming M.D.	No
5	Al Liegel, RPh	Yes
6	Kevin Izard M.D.	Yes-Arrived at 10:25AM
7	Steve Maike RPh	Yes
8	Pat Towers	Yes
9	Alicia Walker PharmD	Yes
10	Michael Witkovsky M.D.	No
11	James Boblin M.D.	Yes-Arrived at 10:10AM
12	Ward Brown, M.D.	No
14	Ronald Diamond, M.D.	Yes- Left at 2:30PM

NOVEMBER 2012 THERAPEUTIC DRUG CLASS

ANTI-HISTAMINES, MINIMALLY SEDATING
BRONCHODILATORS, BETA AGONIST
COPD AGENTS
COUGH AND COLD/NARCOTICS
EPINEPHRINE, SELF-INJECTED
GLUCOCORTICOIDS, INHALED
INTRANASAL RHINITIS AGENTS
LEUKOTRIENE MODIFIERS
ANTI-HYPERURICEMICS, ORAL
BILE SALTS
OPHTHALMIC ANTIBIOTIC/STEROID COMBINATIONS
OPHTHALMIC ANTIBIOTICS
OPHTHALMIC ANTI-INFLAMMATORIES
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS
OPHTHALMICS, GLAUCOMA AGENTS
OTIC ANTIBIOTICS
OTIC ANTI-INFECTIVES & ANESTHETICS
IMMUNOMODULATORS FOR ATOPIC DERMATITIS
STERIODS, TOPICAL-LOW POTENCY
STERIODS, TOPICAL-MEDIUM POTENCY
STERIODS, TOPICAL-HIGH POTENCY
STERIODS, TOPICAL-VERY HIGH POTENCY
CYTOKINE AND CAM ANTAGONISTS
NSAIDS
NEUROPATHIC PAIN-NEW CLASS
ALZHEIMER'S AGENTS
ANTICONVULSANTS
ANTIDEPRESSANTS, OTHER
ANTIDEPRESSANTS, SSRIs
ANTIPARKINSON'S AGENTS
ANTIPSYCHOTICS
SEDATIVE HYPNOTICS
STIMULANTS AND RELATED AGENTS
ANTIPSORIATICS, TOPICAL-NEW CLASS

ANTI-HISTAMINES, MINIMALLY SEDATING						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
LORATADINE TABLETS OTC (ORAL)	44.60%	ON	Yes-Generic			
CETIRIZINE TABLETS OTC (ORAL)	32.90%	ON	Yes-Generic			
CETIRIZINE SOLUTION (ORAL)	6.50%	ON	Yes-Generic			
CETIRIZINE SOLUTION OTC (ORAL)	4.30%	ON	Yes-Generic			
LORATADINE SOLUTION OTC (ORAL)	6.40%	ON	Yes-Generic			
LORATADINE-D OTC (ORAL)	3.20%	ON	Yes-Generic			
SEMPREX-D (ORAL)	0.00%	OFF	No			
LEVOCETIRIZINE TABLETS (ORAL)	0.40%	OFF	No-Generic			
CLARITIN CHEW OTC (ORAL)	0.00%	OFF	No			
CLARINEX TABLET (ORAL)	0.20%	OFF	No			
CETIRIZINE-D OTC (ORAL)	1.40%	ON	Yes-Generic			
CLARINEX SYRUP (ORAL)	0.00%	OFF	No			
CLARINEX ODT (ORAL)	0.00%	OFF	No			
CLARINEX-D 24 HOUR (ORAL)	0.00%	OFF	No			
CLARINEX-D 12 HOUR (ORAL)	0.00%	OFF	No			
LEVOCETIRIZINE SOLUTION (ORAL)	0.10%	OFF	No-Generic			
DESLORATADINE (ORAL)	0.00%	OFF	No-Generic			
XYZAL SOLUTION (ORAL)	0.00%	OFF	No			

- Discussion:
- Rachel Currans-Henry commented that this class includes cost effective OTCs.
- Al Liegel made a motion to accept staff recommendations as presented.
 - Second – Catherine Decker
 - All members were in favor of the motion.
 - Motion passes

BRONCHODILATORS, BETA AGONIST						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
XOPENEX NEB SOLN CONC (INHALATION)	0.00%	OFF	No			
PROVENTIL HFA (INHALATION)	11.50%	ON	Yes			
ALBUTEROL SYRUP (ORAL)	0.20%	ON	Yes-Generic			
METAPROTERENOL SYRUP (ORAL)	0.00%	OFF	No-Generic			
ALBUTEROL NEB SOLN 2.5 MG/3 ML (INHALATION)	13.20%	ON	Yes-Generic			
ALBUTEROL TABLET (ORAL)	0.10%	ON	Yes-Generic			
ALBUTEROL NEB SOLN 100 MG/20 ML (INHALATION)	0.30%	ON	Yes-Generic			
PROAIR HFA (INHALATION)	71.50%	ON	Yes			
ALBUTEROL NEB SOLN 2.5 MG/0.5 ML (INHALATION)	0.00%	ON	Yes-Generic			
VENTOLIN HFA (INHALATION)	0.70%	OFF	No			
TERBUTALINE (ORAL)	0.10%	ON	Yes-Generic			
MAXAIR (INHALATION)	0.20%	ON	Yes			
XOPENEX HFA (INHALATION)	0.50%	OFF	No			
FORADIL (INHALATION)	0.40%	ON	Yes			
SEREVENT (INHALATION)	0.10%	OFF	No			
ALBUTEROL NEB SOLN 0.63, 1.25 MG (INHALATION)	0.60%	OFF	No-Generic			
ALBUTEROL ER (ORAL)	0.00%	ON	Yes-Generic			
XOPENEX NEB SOLN (INHALATION)	0.40%	OFF	No			
METAPROTERENOL TABLET (ORAL)	0.00%	OFF	No-Generic			
ARCAPTA NEOHALER (INHALATION)	0.00%	OFF	No			
LEVALBUTEROL NEB SOLN (INHALATION)	0.00%	OFF	No-Generic			
PERFORMIST (INHALATION)	0.10%	OFF	No			
BROVANA (INHALATION)	0.10%	OFF	No			
LEVALBUTEROL NEB SOLN CONC (INHALATION)	0.00%	OFF	No-Generic			

- Discussion:

- Rick Pope commented that a dose counter for Proair should be available by the end of the year.
- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second –Kevin Izard
 - All members were in favor of this motion.
 - Motion passes

COPD AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
IPRATROPIUM NEBULIZER (INHALATION)	3.90%	ON	Yes-Generic			
IPRATROPIUM / ALBUTEROL (INHALATION)	15.50%	ON	Yes-Generic			
COMBIVENT (INHALATION)	33.70%	ON	Yes			
ATROVENT HFA (INHALATION)	3.80%	ON	Yes			
SPIRIVA (INHALATION)	42.30%	ON	Yes			
COMBIVENT RESPIMAT (INHALATION)	0.00%	OFF	No			
DALIRESP (ORAL)	0.80%	OFF	Yes			

- Discussion:
- Catherine Decker questioned if there is an ICD-9 diagnosis code that is based on spirometry results and previous prednisone use. She also commented that it depends on exacerbations, the types and severity, as to who gets prescribed. Catherine questioned the cost vs. savings.
- Al Liegel questioned how often people with COPD go into the hospital. If it's preferred, it may be prescribed to people who do not end up in the hospital, therefore increasing cost and use where it is not needed. Could it add to costs because they get the drug and still end up in the hospital?
- Kevin Izard commented that there is no ICD-9 for COPD. There is a code for chronic bronchitis and emphysema. It seems best when we have the severity. It is most useful to know if it is mild, severe, etc. If we can't code by severity, then it does not make sense to have a diagnosis restriction at all. He does not feel that Daliresp will be used for anything other than COPD. He questioned who is considered at risk to be able to obtain Daliresp?
- Pat Towers commented that they want this restricted to COPD for those who would likely end up in hospital due to exacerbation. If we can't do that now, maybe we should have it preferred without a diagnosis code. Pat recommends starting with it preferred and see what happens.
- James Boblin commented that runaway use is up to the primary care provider. They need to write the prescriptions and he doesn't see that happening. James recommends preferring for a year with no diagnosis code and see what happens.
- Ronald Diamond questioned what if we leave the diagnosis code off for Daliresp for now and revisit it in a year.
- Rachel Currans-Henry commented that Daliresp would be preferred with a diagnosis restriction. Diagnosis would be for COPD, but not restricted by severity, as it is not an option with ICD-9. ICD-10 allows for severity types and the diagnosis restriction will be revisited when it comes on in 2014. Staff recommendations are to prefer Daliresp and reserve the right to apply a diagnosis code, if appropriate.
- Lynn Radmer commented that SeniorCare members are a significant amount of the utilization for Daliresp. So we would not have medical data available.
- Rick Pope commented that Gold guidelines do not define exacerbations.

- Pat Towers made a motion to accept staff recommendations as presented and for staff to consider diagnosis restrictions for Daliresp, if appropriate.
 - Second – James Boblin
 - The vote was 8-1 in favor of the motion. Al Liegel was opposed to the motion.
 - Motion passes

COUGH AND COLD, NARCOTIC						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
GUAIFENESIN/CODEINE SYRUP (ORAL)	0.90%	ON	Yes-Generic			
GUAIFENESIN/CODEINE SYRUP OTC (ORAL)	45.40%	ON	Yes-Generic			
PROMETHAZINE/CODEINE SYRUP (ORAL)	50.40%	ON	Yes-Generic			
VANACOF CD (ORAL)	0.00%	OFF	No			
PRO-RED AC OTC (ORAL)	0.00%	OFF	No-Generic			
PRO-CLEAR AC OTC (ORAL)	0.00%	OFF	No-Generic			
MYTUSSIN DAC OTC (ORAL)	0.00%	OFF	No-Generic			
PHENYLHISTINE DH OTC (ORAL)	0.00%	OFF	No-Generic			
TUSSIONEX PENNKINETIC SUSPENSION (ORAL)	0.10%	OFF	No			
CHERATUSSIN DAC OTC (ORAL)	0.00%	OFF	No-Generic			
M-CLEAR WC (ORAL)	0.00%	ON	Yes-Generic			
POLY-TUSSIN AC OTC (ORAL)	0.00%	OFF	No-Generic			
M-END PE (ORAL)	0.00%	OFF	No-Generic			
RELCOF C (ORAL)	0.00%	OFF	No-Generic			
M-END WC (ORAL)	0.00%	OFF	No-Generic			
PROMETHAZINE VC/CODEINE SYRUP (ACTAVIS) (ORAL)	0.80%	ON	Yes-Generic			
NEO AC OTC (ORAL)	0.00%	OFF	No-Generic			
POLY-TUSSIN DHC (ORAL)	0.00%	OFF	No-Generic			
DONATUSS DC (ORAL)	0.00%	OFF	No-Generic			
PROMETHAZINE VC/CODEINE SYRUP (QUALITEST) (ORAL)	0.90%	ON	Yes-Generic			
TRYMINE CG OTC (ORAL)	0.00%	OFF	No-Generic			
ALA-HIST AC (ORAL)	0.00%	OFF	No-Generic			
ENDACOF-DC OTC (ORAL)	0.00%	OFF	No-Generic			

MAXIFED-G CD (ORAL)	0.00%	OFF	No-Generic			
MAXIFED CD (ORAL)	0.00%	OFF	No-Generic			
HYDROCODONE/HOMA TROPINE SYRUP (ORAL)	0.10%	OFF	No-Generic			
MAXIFED-G CDX (ORAL)	0.00%	OFF	No-Generic			
MAXIFLU CD (ORAL)	0.00%	OFF	No-Generic			
MAXIPHEN CD (ORAL)	0.00%	OFF	No-Generic			
MAR-COF CG (ORAL)	0.00%	OFF	No-Generic			
MAXIFED CDX (ORAL)	0.00%	OFF	No-Generic			
ALAHIST DHC (ORAL)	0.00%	OFF	No-Generic			
MAXIFLU CDX (ORAL)	0.00%	OFF	No-Generic			
MAXIPHEN CDX (ORAL)	0.00%	OFF	No-Generic			
PHENFLU CD (ORAL)	0.00%	OFF	No-Generic			
CAPCOF (ORAL)	0.00%	OFF	No			
PHENFLU CDX (ORAL)	0.00%	OFF	No-Generic			
MAR-COF BP (ORAL)	0.00%	OFF	No-Generic			
MESEHIST WC (ORAL)	0.00%	OFF	No-Generic			
Z-TUSS AC OTC (ORAL)	0.00%	OFF	No-Generic			
RYDEX OTC (ORAL)	0.00%	OFF	No-Generic			
REZIRA (ORAL)	0.00%	OFF	No			
DEX-TUSS OTC (ORAL)	0.40%	ON	Yes-Generic			
TUSNEL C (ORAL)	0.00%	OFF	No-Generic			
POLY HIST NC (ORAL)	0.00%	OFF	No-Generic			
POLY-TUSSIN EX (ORAL)	0.00%	OFF	No-Generic			
CHLORPHENIRAMINE/C ODEINE LIQUID (ORAL)	0.00%	OFF	No-Generic			
ZUTRIPRO (ORAL)	0.00%	OFF	No			
LORTUSS EX OTC (ORAL)	0.00%	OFF	No-Generic			
TL-HIST CD (ORAL)	0.00%	OFF	No-Generic			
POLY HIST DHC (ORAL)	0.00%	OFF	No-Generic			
CODAR GF (ORAL)	0.00%	OFF	No			
CODAR AR (ORAL)	0.00%	OFF	No			
CODAR D (ORAL)	0.00%	OFF	No			
TRICODE GF (ORAL)	0.00%	OFF	No			
J-MAX DHC (ORAL)	0.00%	OFF	No-Generic			
TRICODE AR (ORAL)	0.00%	OFF	No			
HYDROCODONE/CHLOR PHENIRAMINE SUSP (ORAL)	1.00%	OFF	No-Generic			
J-COF DHC (ORAL)	0.00%	OFF	No-Generic			
ZOTEX-C (ORAL)	0.00%	OFF	No-Generic			

- Discussion: None
- Al Liegel made a motion to accept staff recommendations as presented.
 - Second – Alicia Walker
 - All members were in favor of this motion
 - Motion passes

EPINEPHRINE, SELF-INJECTED						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
EPIPEN (INTRAMUSC)	75.40%	ON	Yes-Generic			
EPIPEN JR (INTRAMUSC)	24.60%	ON	Yes-Generic			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second –Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

GLUCOCORTICOIDS, INHALED						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
QVAR (INHALATION)	5.70%	ON	Yes			
PULMICORT FLEXHALER (INHALATION)	0.30%	OFF	Yes			
FLOVENT DISKUS (INHALATION)	0.90%	ON	Yes			
ALVESCO (INHALATION)	0.10%	OFF	No			
FLOVENT HFA (INHALATION)	24.10%	ON	Yes			
DULERA (INHALATION)	1.30%	ON	Yes			
SYMBICORT (INHALATION)	11.20%	ON	Yes			
ASMANEX (INHALATION)	1.40%	ON	Yes			
ADVAIR HFA (INHALATION)	4.80%	ON	Yes			
ADVAIR DISKUS (INHALATION)	44.10%	ON	Yes			
PULMICORT	0.20%	OFF	No			

0.25, 0.5 MG RESPULES (INHALATION)						
BUDESONIDE 0.25, 0.5 MG RESPULES (INHALATION)	5.60%	OFF	No-Generic			
PULMICORT 1 MG RESPULES (INHALATION)	0.40%	OFF	No			

- Discussion:
- Rachel Currans-Henry commented that the manufacturer of Advair is no longer participating in SeniorCare. Members have shifted to other options with no major disruptions or complaints.
- Steve Maike stated that in the commercial world, you see preferring only one combo product with more cost savings.
- Pat Towers commented that since GlaxoSmithKline (GSK) chose to drop out of SeniorCare, her recommendation is that there should be some consequences. Pat stated that in the future staff may want to consider non-preferring Advair.
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second –Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

INTRANASAL RHINITIS AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
NASONEX (NASAL)	11.10%	ON	Yes			
IPRATROPIUM (NASAL)	1.70%	ON	Yes-Generic			
NASACORT AQ (NASAL)	0.80%	ON	Yes			
ASTEPRO (NASAL)	1.00%	ON	Yes			
ASTELIN (NASAL)	1.60%	ON	Yes			
PATANASE (NASAL)	1.10%	ON	Yes			
BECONASE AQ (NASAL)	0.50%	ON	Yes			
OMNARIS (NASAL)	0.00%	OFF	No			
FLUTICASONE (NASAL)	81.00%	ON	Yes-Generic			
ZETONNA (NASAL)	0.00%	OFF	No			
VERAMYST (NASAL)	0.60%	OFF	No			
QNASL (NASAL)	0.00%	OFF	No			
FLUNISOLIDE (NASAL)	0.10%	OFF	No-Generic			

AZELASTINE (NASAL)	0.10%	OFF	No-Generic			
RHINOCORT AQUA (NASAL)	0.20%	OFF	No			
TRIAMCINOLONE (NASAL)	0.20%	OFF	No-Generic			
DYMISTA (NASAL)	0.00%	OFF	No			

- Discussion: None
- Al Liegel made a motion to accept staff recommendations as presented.
 - Second –Alicia Walker
 - All members were in favor of this motion.
 - Motion passes

LEUKOTRIENE MODIFIERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
MONTELUKAST TABLET (ORAL)	0.00%	ON	Yes-Generic			
MONTELUKAST TAB CHEW (ORAL)	0.00%	ON	Yes-Generic			
MONTELUKAST GRAN PACK (ORAL)	0.00%	OFF	No-Generic			
SINGULAIR GRAN PACK (ORAL)	0.50%	OFF	No			
ZAFIRLUKAST (ORAL)	0.60%	OFF	No-Generic			
ZYFLO CR (ORAL)	0.10%	OFF	No			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second –Kevin Izard
 - All members were in favor of this motion.
 - Motion passes

ANTHYPERURICEMICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ALLOPURINOL (ORAL)	84.10%	ON	Yes-Generic			
PROBENECID / COLCHICINE (ORAL)	2.60%	ON	Yes-Generic			
PROBENECID (ORAL)	1.60%	ON	Yes-Generic			

COLCRYS (ORAL)	6.60%	OFF	No			
ULORIC (ORAL)	5.10%	OFF	No			

- Discussion:
- Lynn Radmer stated that there is indomethacin and naproxen for acute attacks for gout, along with probenecid/colchicine available as preferred on the PDL.
- Al Liegel made a motion to accept staff recommendations as presented.
 - Second –Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

BILE SALTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
URSODIOL 300 MG CAPSULE (ORAL)	76.70%	ON	Yes-Generic			
URSO/URSO FORTE TABLET (ORAL)	0.90%	OFF	No			
URSODIOL TABLET (ORAL)	22.50%	ON	Yes-Generic			
CHENODAL (ORAL)	0.00%	OFF	No-Generic			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second –Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

OPHTHALMIC ANTIBIOTIC-STEROID COMBINATIONS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BLEPHAMIDE (OPHTHALMIC)	2.00%	ON	Yes			
TOBRADEX SUSPENSION (OPHTHALMIC)	30.90%	ON	Yes			
BLEPHAMIDE S.O.P. (OPHTHALMIC)	1.00%	ON	Yes			
NEOMYCIN/POLYMYXIN/D EXAMETHASONE (OPHTHALMIC)	38.10%	ON	Yes-Generic			
TOBRADEX ST (OPHTHALMIC)	0.00%	OFF	No			
PRED-G DROPS SUSP (OPHTHALMIC)	0.10%	ON	Yes			
TOBRADEX OINTMENT (OPHTHALMIC)	13.80%	ON	Yes			

PRED-G OINT. (OPHTHALMIC)	0.30%	ON	Yes			
SULFACETAMIDE / PREDNISOLONE (OPHTHALMIC)	2.60%	ON	Yes-Generic			
ZYLET (OPHTHALMIC)	7.50%	ON	Yes			
TOBRAMYCIN / DEXAMETHASONE SUSPENSION (OPHTHALMIC)	3.60%	OFF	No-Generic			
NEOMYCIN/BACITRACIN/P OLY/HC (OPHTHALMIC)	0.00%	OFF	No-Generic			
NEOMYCIN/POLYMYXIN/H C (OPHTHALMIC)	0.10%	OFF	No-Generic			

- Discussion:
- Rachel Currans-Henry stated that this is the first annual review of this class and that we have achieved a 96% preferred product compliance rate.
- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second –Steve Maike
 - All members were in favor of this motion.
 - Motion passes

OPHTHALMIC ANTIBIOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
GENTAMICIN DROPS (OPHTHALMIC)	10.00%	ON	Yes-Generic			
SULFACETAMIDE SOLUTION (OPHTHALMIC)	5.50%	ON	Yes-Generic			
TOBRAMYCIN (OPHTHALMIC)	7.10%	ON	Yes-Generic			
OFLOXACIN (OPHTHALMIC)	5.90%	ON	Yes-Generic			
CIPROFLOXACIN SOLUTION (OPHTHALMIC)	9.70%	ON	Yes-Generic			
TOBREX OINTMENT (OPHTHALMIC)	0.40%	ON	Yes			
MOXEZA (OPHTHALMIC)	0.00%	OFF	Yes			
VIGAMOX (OPHTHALMIC)	13.40%	ON	Yes			
POLYMYXIN/TRIMETHOPRIM (OPHTHALMIC)	25.50%	ON	Yes-Generic			
GENTAMICIN OINT. (OPHTHALMIC)	1.10%	ON	Yes-Generic			
ERYTHROMYCIN (OPHTHALMIC)	20.60%	ON	Yes-Generic			
NEOMYCIN-POLYMYXIN-GRAMICIDIN (OPHTHALMIC)	0.00%	OFF	No-Generic			
BESIVANCE (OPHTHALMIC)	0.30%	ON	Yes			
CILOXAN OINTMENT (OPHTHALMIC)	0.30%	ON	Yes			
BACITRACIN/POLYMYXIN B SULFATE OINT. (OPHTHALMIC)	0.00%	OFF	No-Generic			

ZYMAR (OPHTHALMIC)	0.00%	ON	No			
ZYMAXID (OPHTHALMIC)	0.00%	OFF	No			
NEOMYCIN/BACITRACIN/P OLYMYXIN OINT (OPHTHALMIC)	0.00%	OFF	No-Generic			
AZASITE (OPHTHALMIC)	0.20%	OFF	No			
QUIXIN (OPHTHALMIC)	0.00%	OFF	No			
BACITRACIN (OPHTHALMIC)	0.00%	OFF	No-Generic			
SULFACETAMIDE OINTMENT (OPHTHALMIC)	0.00%	ON	Yes-Generic			
LEVOFLOXACIN (OPHTHALMIC)	0.00%	OFF	No-Generic			
NATACYN (OPHTHALMIC)	0.00%	OFF	No			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second –Al Liegel
 - All members were in favor of this motion.
 - Motion passes

OPHTHALMICS, ANTI-INFLAMMATORIES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
FLUOROMETHOLONE (OPHTHALMIC)	8.40%	ON	Yes-Generic			
LOTEMAX DROPS (OPHTHALMIC)	9.10%	ON	Yes			
PRED MILD (OPHTHALMIC)	0.80%	ON	Yes			
MAXIDEX (OPHTHALMIC)	0.30%	ON	Yes			
DICLOFENAC (OPHTHALMIC)	16.00%	ON	Yes-Generic			
FLAREX (OPHTHALMIC)	0.50%	ON	Yes			
FLURBIPROFEN (OPHTHALMIC)	1.30%	ON	Yes-Generic			
FML FORTE (OPHTHALMIC)	0.30%	ON	Yes			
PREDNISOLONE ACETATE (OPHTHALMIC)	54.80%	ON	Yes-Generic			
FML S.O.P. (OPHTHALMIC)	1.10%	ON	Yes			
KETOROLAC LS (OPHTHALMIC)	0.50%	OFF	No-Generic			
KETOROLAC (OPHTHALMIC)	0.30%	OFF	No-Generic			
DEXAMETHASONE (OPHTHALMIC)	2.00%	ON	Yes-Generic			
VEXOL (OPHTHALMIC)	0.00%	OFF	No			

NEVANAC (OPHTHALMIC)	0.30%	OFF	No			
PREDNISOLONE SOD PHOSPHATE (OPHTHALMIC)	0.00%	OFF	No-Generic			
DUREZOL (OPHTHALMIC)	0.80%	OFF	No			
LOTEMAX OINTMENT (OPHTHALMIC)	0.10%	OFF	No			
PRED FORTE (OPHTHALMIC)	2.70%	ON	No			
BROMDAY (OPHTHALMIC)	0.30%	OFF	No			
ACUVAIL (OPHTHALMIC)	0.00%	OFF	No			
BROMFENAC (OPHTHALMIC)	0.30%	OFF	No-Generic			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second –Steve Maike
 - All members were in favor of this motion.
 - Motion passes

OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BEPREVE (OPHTHALMIC)	0.20%	OFF	No			
ALREX (OPHTHALMIC)	2.70%	ON	Yes			
CROMOLYN SODIUM (OPHTHALMIC)	4.10%	ON	Yes-Generic			
OPTIVAR (OPHTHALMIC)	4.00%	ON	No			
PATADAY (OPHTHALMIC)	87.40%	ON	Yes			
EMADINE (OPHTHALMIC)	0.00%	OFF	No			
ALOMIDE (OPHTHALMIC)	0.00%	OFF	No			
PATANOL (OPHTHALMIC)	1.40%	OFF	No			
LASTACFT (OPHTHALMIC)	0.10%	OFF	No			
ALOCRI (OPHTHALMIC)	0.00%	OFF	No			
AZELASTINE (OPHTHALMIC)	0.10%	OFF	No-Generic			
EPINASTINE (OPHTHALMIC)	0.00%	OFF	No-Generic			

- Discussion: None

- Al Liegel made a motion to accept staff recommendations as presented.
 - Second –Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

OPHTHALMICS, GLAUCOMA AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BETAXOLOL (OPHTHALMIC)	0.10%	ON	Yes-Generic			
LATANOPROST 2.5 ML (OPHTHALMIC)	3.60%	OFF	Yes-Generic			
AZOPT (OPHTHALMIC)	4.20%	ON	Yes			
IOPIDINE (OPHTHALMIC)	0.00%	OFF	No			
ALPHAGAN P 0.15% (OPHTHALMIC)	5.20%	ON	Yes			
ISTALOL (OPHTHALMIC)	0.00%	OFF	No			
BETIMOL (OPHTHALMIC)	1.10%	ON	Yes			
TRAVATAN / TRAVATAN Z 2.5 ML (OPHTHALMIC)	37.90%	ON	Yes			
LEVOBUNOLOL (OPHTHALMIC)	1.20%	ON	Yes-Generic			
CARTEOLOL (OPHTHALMIC)	0.20%	ON	Yes-Generic			
DORZOLAMIDE (OPHTHALMIC)	2.50%	ON	Yes-Generic			
BRIMONIDINE (OPHTHALMIC)	4.00%	ON	Yes-Generic			
TIMOLOL (OPHTHALMIC)	14.70%	ON	Yes-Generic			
BETOPTIC S (OPHTHALMIC)	0.90%	ON	Yes			
METIPRANOLOL (OPHTHALMIC)	0.10%	ON	Yes-Generic			
TRAVATAN / TRAVATAN Z 5 ML (OPHTHALMIC)	5.90%	ON	Yes			
COMBIGAN (OPHTHALMIC)	5.30%	ON	Yes			
LUMIGAN 2.5ML (OPHTHALMIC)	1.50%	OFF	No			
PILOCARPINE (OPHTHALMIC)	1.20%	ON	Yes-Generic			
ALPHAGAN P 0.1% (OPHTHALMIC)	0.90%	OFF	No			
ZIOPTAN (OPHTHALMIC)	0.00%	OFF	No			
DORZOLAMIDE / TIMOLOL (OPHTHALMIC)	8.50%	ON	Yes-Generic			
COSOPT PF (OPHTHALMIC)	0.00%	OFF	Yes			
LUMIGAN 5ML (OPHTHALMIC)	0.40%	OFF	No			
APRACLOUIDINE (OPHTHALMIC)	0.10%	OFF	No-Generic			
BRIMONIDINE P 0.15% (OPHTHALMIC)	0.30%	OFF	No-Generic			

- Discussion: None

- Steve Maike made a motion to accept staff recommendations as presented.
 - Second –Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

OTIC ANTIBIOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
OFLOXACIN (OTIC)	25.70%	ON	Yes-Generic			
NEOMYCIN/POLYMYXIN/HC SOLN/SUSP (OTIC)	41.10%	ON	Yes-Generic			
COLY-MYCIN S (OTIC)	0.00%	ON	Yes			
CIPRODEX (OTIC)	22.20%	ON	Yes			
CORTISPORIN-TC (OTIC)	0.00%	OFF	No			
CIPRO HC (OTIC)	10.90%	ON	No			

- Discussion:
- Kevin Izard requested an explanation for the switch from Cipro HC to Ciprodex. Rick Pope replied to Kevin Izard’s question stating that the switch was a moderate cost savings. Ciprodex comes out at a better cost and the manufacturer no longer supports Cipro HC.
- Rachel Currans-Henry stated that the change is supported by the manufacturer based on today’s public testimony.
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second –Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

OTIC ANTI-INFECTIVES & ANESTHETICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ANTIPYRINE / BENZOCAINE (OTIC)	86.70%	ON	Yes-Generic			
ACETIC ACID (OTIC)	4.40%	ON	Yes-Generic			
ACETIC ACID/ALUMINUM (OTIC)	0.60%	ON	No-Generic			
PINNACAINE (OTIC)	0.10%	ON	No-Generic			
OTOZIN (OTIC)	0.00%	OFF	No-Generic			
OTIC CARE (OTIC)	0.00%	OFF	No			
MYOXIN (OTIC)	0.00%	OFF	No-Generic			
TRIOXIN (OTIC)	0.00%	OFF	No-Generic			
TREAGAN OTIC (OTIC)	0.00%	OFF	No-Generic			
ACETIC ACID HC (OTIC)	8.30%	ON	No-Generic			

- Discussion: None
- Al Liegel made a motion to accept staff recommendations as presented.
 - Second –Pat Towers
 - All members were in favor of this motion.
 - Motion passes

IMMUNOMODULATORS, ATOPIC DERMATITIS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ELIDEL (TOPICAL)	46.00%	OFF	No			
PROTOPIC (TOPICAL)	54.00%	OFF	No			

- Discussion: None
- Alicia Walker made a motion to accept staff recommendations as presented.
 - Second –Al Liegel
 - All members in favor of this motion.
 - Motion passes

STEROIDS, TOPICAL LOW						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
HYDROCORTISONE CREAM (TOPICAL)	44.60%	ON	Yes-Generic			
DESONIDE CREAM (TOPICAL)	9.50%	ON	Yes-Generic			
CAPEX SHAMPOO (TOPICAL)	0.20%	OFF	No			
HYDROCORTISONE OINT. (TOPICAL)	31.70%	ON	Yes-Generic			
DESONIDE OINT. (TOPICAL)	10.70%	ON	Yes-Generic			
HYDROCORTISONE / MIN OIL / PET OINT. (TOPICAL)	0.00%	ON	Yes-Generic			
HYDROCORTISONE/ALOE GEL (TOPICAL)	0.00%	OFF	No-Generic			
DERMA-SMOOTHIE-FS (TOPICAL)	0.20%	OFF	No			
ALCLOMETASONE DIPROPIONATE CREAM (TOPICAL)	0.00%	OFF	No-Generic			
DESONIDE LOTION (TOPICAL)	0.10%	OFF	No-Generic			
FLUOCINOLONE 0.01% OIL (TOPICAL)	0.70%	OFF	Yes-Generic			
HYDROCORTISONE LOTION (TOPICAL)	2.10%	ON	Yes-Generic			
ALCLOMETASONE DIPROPIONATE OINT. (TOPICAL)	0.00%	OFF	No-Generic			
HYDROCORTISONE ACETATE / UREA	0.00%	OFF	No-Generic			

(TOPICAL)						
DESONATE GEL (TOPICAL)	0.00%	OFF	No			
VERDESO (TOPICAL)	0.00%	OFF	No			

- Discussion:
- Rick Pope stated that there are multiple drugs available in all four steroid classes.
- Steve Maiké expressed concern that the removal of flucocinolone acetonide could shift members to higher potency topical steroids at a higher cost.
- Rick Pope responded that the costs of higher potency drugs are comparable across classes.
- Kimberly Smithers explained that we include preferred drugs or a reference to the PDL quick reference in real-time claim responses.

- Al Liegel made a motion to accept staff recommendations as presented.
 - Second –Kevin Izard
 - All members were in favor of this motion.
 - Motion passes

STEROIDS, TOPICAL MEDIUM						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
MOMETASONE FUROATE SOLUTION (TOPICAL)	0.20%	OFF	No-Generic			
PANDEL (TOPICAL)	0.00%	OFF	No			
HYDROCORTISONE BUTYRATE SOLUTION BRAND (TOPICAL)	0.00%	OFF	Yes-Generic			
HYDROCORTISONE BUTYRATE SOLUTION (TOPICAL)	0.00%	OFF	Yes-Generic			
HYDROCORTISONE BUTYRATE OINT. (TOPICAL)	0.00%	OFF	Yes-Generic			
HYDROCORTISONE BUTYRATE OINT. BRAND (TOPICAL)	0.00%	OFF	Yes-Generic			
HYDROCORTISONE VALERATE CREAM (TOPICAL)	20.10%	ON	Yes-Generic			
HYDROCORTISONE VALERATE OINT. (TOPICAL)	9.60%	ON	Yes-Generic			
FLUTICASONE PROPIONATE CREAM (TOPICAL)	31.80%	ON	Yes-Generic			
CLODERM (TOPICAL)	1.10%	ON	No			
MOMETASONE FUROATE CREAM	1.20%	OFF	No-Generic			

(TOPICAL)						
HYDROCORTISONE BUTYRATE CREAM BRAND (TOPICAL)	0.00%	OFF	No-Generic			
FLUTICASONE PROPIONATE OINT. (TOPICAL)	12.30%	ON	Yes-Generic			
PREDNICARBATE CREAM (TOPICAL)	0.10%	OFF	No-Generic			
LUXIQ (TOPICAL)	0.40%	OFF	No			
MOMETASONE FUROATE OINT. (TOPICAL)	0.60%	OFF	No-Generic			
PREDNICARBATE OINT. (TOPICAL)	0.00%	OFF	No-Generic			
HYDROCORTISONE BUTYRATE CREAM (TOPICAL)	0.10%	OFF	No-Generic			
FLUOCINOLONE ACETONIDE OINT. (TOPICAL)	10.40%	ON	No-Generic			
FLUOCINOLONE ACETONIDE CREAM (TOPICAL)	5.60%	ON	No-Generic			
FLUOCINOLONE ACETONIDE SOLUTION (TOPICAL)	5.40%	ON	No-Generic			
CUTIVATE LOTION (TOPICAL)	0.00%	OFF	No			
CORDRAN TAPE (TOPICAL)	0.80%	OFF	No			
MOMEXIN (TOPICAL)	0.00%	OFF	No			
FLUTICASONE PROPIONATE LOTION (TOPICAL)	0.10%	OFF	No-Generic			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second –Kevin Izard
 - All members were in favor of this motion.
 - Motion passes

STERIODS, TOPICAL HIGH						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TRIAMCINOLONE ACETONIDE CREAM (TOPICAL)	51.40%	ON	Yes-Generic			
BETAMETHASONE VALERATE CREAM (TOPICAL)	1.90%	ON	Yes-Generic			

FLUOCINONIDE CREAM (TOPICAL)	3.10%	ON	Yes-Generic			
TRIAMCINOLONE ACETONIDE OINT. (TOPICAL)	28.00%	ON	Yes-Generic			
BETAMET DIPROP / PROP GLY CREAM (TOPICAL)	0.00%	OFF	No-Generic			
BETAMETHASONE DIPROPIONATE CREAM (TOPICAL)	3.30%	OFF	Yes-Generic			
BETAMETHASONE DIPROPIONATE LOTION (TOPICAL)	1.00%	OFF	Yes-Generic			
HALOG CREAM (TOPICAL)	0.00%	OFF	No			
FLUOCINONIDE EMOLLIENT (TOPICAL)	0.60%	ON	Yes-Generic			
FLUOCINONIDE SOLUTION (TOPICAL)	1.70%	ON	Yes-Generic			
HALOG OINT. (TOPICAL)	0.00%	OFF	No			
FLUOCINONIDE GEL (TOPICAL)	0.30%	ON	Yes-Generic			
KENALOG AEROSOL (TOPICAL)	0.00%	OFF	No			
TRIAMCINOLONE ACETONIDE LOTION (TOPICAL)	0.10%	OFF	No-Generic			
BETAMETHASONE VALERATE OINT. (TOPICAL)	2.00%	ON	Yes-Generic			
FLUOCINONIDE OINT. (TOPICAL)	4.20%	ON	Yes-Generic			
BETAMETHASONE VALERATE LOTION (TOPICAL)	0.70%	ON	Yes-Generic			
DESOXIMETASONE GEL (TOPICAL)	0.00%	OFF	No-Generic			
BETAMET DIPROP / PROP GLY LOTION (TOPICAL)	0.00%	OFF	No-Generic			
BETAMETHASONE DIPROPIONATE GEL (TOPICAL)	0.00%	OFF	No-Generic			
BETAMETHASONE DIPROPIONATE OINT. (TOPICAL)	1.50%	OFF	Yes-Generic			
AMCINONIDE CREAM (TOPICAL)	0.00%	OFF	No-Generic			
AMCINONIDE LOTION (TOPICAL)	0.00%	OFF	No-Generic			
BETAMET DIPROP / PROP GLY OINT. (TOPICAL)	0.10%	OFF	No-Generic			
VANOS (TOPICAL)	0.00%	OFF	No			
DIFLORASONE	0.00%	OFF	No-Generic			

DIACETATE OINT. (TOPICAL)						
DIFLORASONE DIACETATE CREAM (TOPICAL)	0.00%	OFF	No-Generic			
AMCINONIDE OINT. (TOPICAL)	0.00%	OFF	No-Generic			
DESOXIMETASONE CREAM (TOPICAL)	0.10%	OFF	No-Generic			
DESOXIMETASONE OINT.(TOPICAL)	0.00%	OFF	No-Generic			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second –Steve Maike
 - All members were in favor of this motion.
 - Motion passes

STEROIDS, TOPICAL VERY HIGH						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLOBEX LOTION (TOPICAL)	0.00%	OFF	No			
CLOBEX SHAMPOO (TOPICAL)	0.10%	OFF	No			
CLOBETASOL PROPIONATE CREAM (TOPICAL)	29.20%	ON	Yes-Generic			
CLOBETASOL PROPIONATE OINT. (TOPICAL)	38.90%	ON	Yes-Generic			
CLOBETASOL PROPIONATE SOLUTION (TOPICAL)	20.20%	ON	Yes-Generic			
CLOBETASOL PROPIONATE GEL (TOPICAL)	2.20%	ON	Yes-Generic			
HALOBETASOL PROPIONATE CREAM (TOPICAL)	1.80%	ON	Yes-Generic			
CLOBETASOL EMOLLIENT (TOPICAL)	3.00%	ON	Yes-Generic			
HALOBETASOL PROPIONATE OINT. (TOPICAL)	3.30%	ON	Yes-Generic			
HALAC (TOPICAL)	0.00%	OFF	No-Generic			
CLOBETASOL PROPIONATE	0.30%	OFF	No-Generic			

FOAM (TOPICAL)						
APEXICON E (TOPICAL)	0.20%	ON	No			
CLOBEX SPRAY (TOPICAL)	0.30%	OFF	No			
OLUX-E (TOPICAL)	0.00%	OFF	No			
HALONATE (TOPICAL)	0.00%	OFF	No			
CLOBETASOL SHAMPOO (AG) (TOPICAL)	0.20%	OFF	No-Generic			
CLOBETASOL SHAMPOO (TOPICAL)	0.30%	OFF	No-Generic			
CLOBETASOL LOTION (AG) (TOPICAL)	0.00%	OFF	No-Generic			
CLOBETASOL LOTION (TOPICAL)	0.10%	OFF	No-Generic			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second –Steve Maike
 - All members were in favor of this motion.
 - Motion passes

CYTOKINE AND CAM ANTAGONISTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ENBREL KIT (INJECTION)	1.80%	ON	Yes			
CIMZIA SYRINGE KIT (INJECTION)	6.60%	ON	Yes			
KINERET (INJECTION)	0.60%	OFF	No			
CIMZIA KIT (INJECTION)	0.70%	ON	Yes			
SIMPONI DISP SYRINGE (INJECTION)	0.20%	OFF	No			
ENBREL DISP SYRINGE (INJECTION)	9.80%	ON	Yes			
ENBREL PEN (INJECTION)	22.50%	ON	Yes			
HUMIRA PEN IJ KIT (INJECTION)	44.40%	ON	Yes			
HUMIRA KIT (INJECTION)	10.10%	ON	Yes			

SIMPONI PEN INJECTER (INJECTION)	1.00%	OFF	No			
ORENCIA (SUB-Q)	2.30%	OFF	No			

- Discussion:
- Rachel Currans-Henry stated to the committee that all of the drugs in this class require clinical PA, regardless of preferred or non-preferred status. One change is to require trial with two preferred agents before a non-preferred agent. Also, there will be a new form for Ulcerative Colitis.
- Steve Maike stated that employers say that 50% of their drug spend is touched by specialty drugs, and it represents a .5% of patients. The employers are interested to see the outcomes. There are also oral drugs on the horizon, very soon.
- Rick Pope commented that Humira is approved for all the indications represented by the Cytokine/CAM group.
- Kevin Izard questioned how the clinical PA works.
- Lynn Radmer stated that each indication has its own prior authorization form. Each form goes through the usual treatment options for the specific condition, and if the first line agents have been tried, or cannot be used, you can get to a preferred Cytokine/CAM.
- Catherine Decker stated that there is no single drug that is approved for all the indications. She questioned if we are discussing limiting these drugs to certain specialty pharmacies.
- Rachel Currans-Henry stated that all drugs on the PDL are available to all pharmacies, not limited to certain specialty pharmacies.
- Pat Towers questioned if there should be public/ private partners in this area to maximize savings. We should try to get better offers by limiting it to one preferred product. Pat suggested that Brett Davis should talk to other employer groups about joining together.
- James Boblin stated that if there are no studies showing superiority of one drug over another drug, then we should choose the cheapest one.
- Alicia Walker made a motion to accept staff recommendations as presented but continue the clinical management of the class with a requirement to use two preferred products before a non-preferred product is approved.
 - Second –Kevin Izard
 - All members were in favor of this motion.
 - Motion passes

NSAIDS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PIROXICAM (ORAL)	1.20%	ON	Yes-Generic			
IBUPROFEN TABLET OTC (ORAL)	1.40%	ON	Yes-Generic			
MELOXICAM TABLET (ORAL)	11.30%	ON	Yes-Generic			
IBUPROFEN TABLET (ORAL)	34.00%	ON	Yes-Generic			
NAPROXEN SODIUM OTC (ORAL)	0.30%	ON	Yes-Generic			
IBUPROFEN SUSPENSION OTC (ORAL)	0.80%	ON	Yes-Generic			

NAPROXEN TABLET (ORAL)	17.00%	ON	Yes-Generic			
NAPROXEN SODIUM (ORAL)	1.40%	ON	Yes-Generic			
IBUPROFEN TAB CHEW OTC (ORAL)	0.00%	ON	Yes-Generic			
KETOROLAC (ORAL)	1.90%	ON	Yes-Generic			
IBUPROFEN SUSPENSION (ORAL)	8.60%	ON	Yes-Generic			
IBUPROFEN DROPS SUSPENSION OTC (ORAL)	0.10%	ON	Yes-Generic			
DICLOFENAC POTASSIUM (ORAL)	0.70%	ON	Yes-Generic			
IBUPROFEN CAPSULE OTC (ORAL)	0.00%	ON	Yes-Generic			
OXAPROZIN (ORAL)	0.10%	ON	Yes-Generic			
KETOPROFEN (ORAL)	0.40%	ON	Yes-Generic			
INDOCIN SUSPENSION (ORAL)	0.00%	OFF	No			
NAPROXEN EC (ORAL)	0.80%	ON	Yes-Generic			
INDOMETHACIN CAPSULE (ORAL)	2.30%	ON	Yes-Generic			
SULINDAC (ORAL)	0.40%	ON	Yes-Generic			
ETODOLAC (ORAL)	1.00%	ON	Yes-Generic			
DICLOFENAC SR (ORAL)	0.40%	ON	Yes-Generic			
FLURBIPROFEN (ORAL)	0.00%	ON	Yes-Generic			
NAPROXEN SUSPENSION (ORAL)	0.20%	ON	Yes-Generic			
NABUMETONE (ORAL)	0.50%	OFF	No-Generic			
DICLOFENAC SODIUM (ORAL)	8.70%	ON	Yes-Generic			
VOLTAREN (TOPICAL)	3.30%	ON	Yes			
VIMOVO (ORAL)	0.00%	OFF	No			
MELOXICAM SUSPENSION (ORAL)	0.00%	OFF	No-Generic			
ETODOLAC TAB SR (ORAL)	0.00%	OFF	No-Generic			
DUEXIS (ORAL)	0.00%	OFF	No			
ARTHROTEC (ORAL)	0.10%	OFF	No			
TOLMETIN SODIUM CAPSULE	0.00%	OFF	No-Generic			

(ORAL)						
CELEBREX (ORAL)	2.50%	OFF	No			
FENOPROFEN (ORAL)	0.00%	OFF	No-Generic			
PENNSAID (TOPICAL)	0.10%	OFF	No			
INDOMETHACIN CAPSULE ER (ORAL)	0.10%	OFF	No-Generic			
TOLMETIN SODIUM TABLET (ORAL)	0.00%	OFF	No-Generic			
FLECTOR (TOPICAL)	0.10%	OFF	No			
MECLOFENAMATE (ORAL)	0.00%	OFF	No-Generic			
SPRIX (NASAL)	0.00%	OFF	No			
ZIPSOR (ORAL)	0.00%	OFF	No			
DIFLUNISAL (ORAL)	0.00%	OFF	No-Generic			
KETOPROFEN ER (ORAL)	0.00%	OFF	No-Generic			
MEFENAMIC ACID (ORAL)	0.00%	OFF	No-Generic			
PONSTEL(ORAL)	0.00%	OFF	No			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second –Alicia Walker
 - All members were in favor of this motion.
 - Motion passes

NEUROPATHIC PAIN						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
GABAPENTIN CAPSULE (ORAL)	45.40%	ON	Yes-Generic			
CAPSAICIN OTC (TOPICAL)	0.50%	ON	Yes-Generic			
GABAPENTIN TABLET (ORAL)	14.70%	ON	Yes-Generic			
SAVELLA DS PK (ORAL)	0.20%	ON	Yes			
SAVELLA (ORAL)	2.80%	ON	Yes			
GABAPENTIN SOLUTION (ORAL)	0.50%	ON	Yes-Generic			
CYMBALTA (ORAL)	13.70%	OFF	Yes			
GRALISE (ORAL)	0.00%	OFF	No			

LYRICA (ORAL)	18.50%	ON	Yes			
LIDODERM (TOPICAL)	3.60%	OFF	No			
HORIZANT (ORAL)	0.00%	NR	No			

- Discussion:
- Rachel Currans-Henry stated that Provider Synergies has combined the Fibromyalgia and Analgesics/Anesthetics, Topical classes to create a new neuropathic pain class. DHS staff may represent some of the drugs in more than one class on the PDL quick reference. But the drugs will only be reviewed in the neuropathic pain class.
- Brett Davis stated that preferring a drug such as Cymbalta, which is approved for multiple conditions, may save costs by only having to take a single drug instead of two. It may also help medication adherence with limited financial risk, due to Cymbalta going generic soon.
- Kevin Izard stated that most fibromyalgia patients also have depression or other pain, so it makes sense to have this product preferred.
- Steve Maike stated that over the years we think of downstream ramifications of adding brand products, in this case Cymbalta being preferred may also have a trickle-down increased cost effect to the antidepressant classes.
- James Boblin commented that Cymbalta goes generic late next year, so the risk should be low for the cost getting out of hand.
- Ronald Diamond stated that clinically, Cymbalta is not a first line drug.
- James Boblin made a motion to accept staff recommendations as presented.
 - Second –Pat Towers
 - The vote was 8-1 in favor of the motion. Steve Maike was opposed to the motion.
 - Motion passes

ALZHEIMER'S AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DONEPEZIL (ORAL)	53.40%	ON	Yes-Generic			
EXELON CAPSULES (ORAL)	1.50%	ON	Yes			
DONEPEZIL ODT (ORAL)	0.20%	ON	Yes-Generic			
GALANTAMINE ER (ORAL)	1.50%	OFF	No-Generic			
NAMENDA TABS PK (ORAL)	0.30%	ON	Yes			
EXELON (TRANSDERM.)	5.30%	ON	Yes			
EXELON SOLUTION (ORAL)	0.00%	OFF	No			
NAMENDA TABLET (ORAL)	35.20%	ON	Yes			
ARICEPT 23 MG (ORAL)	0.80%	OFF	No			
GALANTAMINE TABLET	1.30%	OFF	No-Generic			

(ORAL)						
RIVASTIGMINE CAPSULES (ORAL)	0.20%	OFF	No-Generic			
NAMENDA SOLUTION (ORAL)	0.20%	ON	Yes			
GALANTAMINE SOLUTION (ORAL)	0.00%	OFF	No-Generic			

- Discussion:
- Rachel Currans-Henry informed the committee that last year Exelon capsules were preferred over the generic and that status remains in place today.
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second –Al Liegel
 - All members were in favor of this motion.
 - Motion passes

ANTICONVULSANTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLONAZEPAM (ORAL)	37.50%	ON	Yes-Generic			
LAMOTRIGINE TAB DS PK (ORAL)	0.00%	ON	Yes-Generic			
CARBAMAZEPINE TABLET (ORAL)	2.10%	ON	Yes-Generic			
TOPIRAMATE TABLETS (ORAL)	9.70%	ON	Yes-Generic			
LAMOTRIGINE (ORAL)	15.30%	ON	Yes-Generic			
TEGRETOL XR (ORAL)	0.40%	ON	Yes			
PRIMIDONE (ORAL)	0.90%	ON	Yes-Generic			
DIVALPROEX TABLET (ORAL)	4.10%	ON	Yes-Generic			
PHENOBARBITAL TABLET (ORAL)	2.40%	ON	Yes-Generic			
VALPROATE SYRUP (ORAL)	0.90%	ON	Yes-Generic			
PHENOBARBITAL ELIXIR (ORAL)	0.60%	ON	Yes-Generic			
CARBAMAZEPINE TAB CHEW (ORAL)	0.70%	ON	Yes-Generic			
ZONISAMIDE (ORAL)	1.20%	ON	Yes-Generic			
CELONTIN (ORAL)	0.00%	ON	Yes			
PHENYTOIN (ORAL)	1.20%	ON	Yes-Generic			
VALPROIC ACID (ORAL)	0.20%	ON	Yes-Generic			
LEVETIRACETAM TABLETS (ORAL)	5.10%	ON	Yes-Generic			

ETHOSUXIMIDE SYRUP (ORAL)	0.10%	ON	Yes-Generic			
OXCARBAZEPINE TABLETS (ORAL)	2.20%	ON	Yes-Generic			
PHENYTOIN EXT CAPSULE (GENERIC PHENYTEK) (ORAL)	0.10%	ON	Yes-Generic			
DIVALPROEX ER (ORAL)	6.10%	ON	Yes-Generic			
PHENYTOIN SUSPENSION (ORAL)	0.10%	ON	Yes-Generic			
DEPAKOTE SPRINKLE (ORAL)	1.30%	ON	Yes			
STAVZOR (ORAL)	0.00%	OFF	No			
LEVETIRACETAM SOLUTION (ORAL)	1.80%	ON	Yes-Generic			
LEVETIRACETAM ER (ORAL)	0.30%	ON	Yes-Generic			
PEGANONE (ORAL)	0.00%	ON	Yes			
CARBAMAZEPINE SUSPENSION (ORAL)	0.20%	ON	Yes-Generic			
GABITRIL (ORAL)	0.10%	ON	Yes			
DILANTIN INFATAB (ORAL)	0.20%	ON	Yes-Generic			
EQUETRO (ORAL)	0.00%	OFF	No			
CARBAMAZEPINE XR (ORAL)	0.10%	OFF	No-Generic			
CLONAZEPAM ODT (ORAL)	0.20%	OFF	No-Generic			
LAMICTAL TAB DS PK (ORAL)	0.10%	ON	Yes			
CARBATROL (ORAL)	1.00%	ON	Yes			
ETHOSUXIMIDE CAPSULE (ORAL)	0.20%	ON	Yes-Generic			
CARBAMAZEPINE ER (GENERIC CARBATROL) (ORAL)	0.00%	OFF	Yes-Generic			
TOPIRAMATE SPRINKLE (ORAL)	0.30%	ON	Yes-Generic			
FELBATOL TABLET (ORAL)	0.30%	ON	Yes			
DIVALPROEX SPRINKLE (ORAL)	0.20%	OFF	No-Generic			
PHENYTEK (ORAL)	0.00%	OFF	No-Generic			
OXCARBAZEPINE SUSPENSION (ORAL)	0.00%	ON	Yes-Generic			
DIASTAT (RECTAL)	0.50%	ON	Yes			
FELBATOL SUSPENSION (ORAL)	0.30%	ON	Yes			
LAMICTAL ODT DS PK (ORAL)	0.00%	OFF	No			
VIMPAT (ORAL)	0.60%	OFF	No			
VIMPAT SOLUTION (ORAL)	0.10%	OFF	No			
ONFI (ORAL)	0.20%	OFF	No			

LAMICTAL ODT (ORAL)	0.20%	OFF	No			
DIAZEPAM (RECTAL)	0.00%	OFF	No-Generic			
POTIGA (ORAL)	0.00%	OFF	No			
LAMICTAL XR (ORAL)	0.40%	OFF	No			
BANZEL TABLET (ORAL)	0.20%	OFF	No			
FELBAMATE SUSPENSION (ORAL)	0.00%	OFF	No-Generic			
LAMICTAL XR DS PK (ORAL)	0.10%	OFF	No			
FELBAMATE TABLET (ORAL)	0.00%	OFF	No-Generic			
BANZEL SUSPENSION (ORAL)	0.00%	OFF	No			
SABRIL TABLET(ORAL)	0.00%	OFF	No			
SABRIL POWDER PACK(ORAL)	0.00%	OFF	No			

- Discussion:
- James Boblin pointed out that the argument for complete open access to these drugs is no longer warranted, considering neurologists have plenty of anticonvulsant drug choices available. In his opinion, it is acceptable to employ restrictions with new high cost drugs with limited indications and severe side effect profiles.
- Kevin Izard noted that this class also includes Lyrica and gabapentin.
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second –James Boblin
 - All members were in favor of this motion.
 - Motion passes

ANTIDEPRESSANTS, OTHER						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
VENLAFAXINE ER TABLETS (UPSTATE) (ORAL)	0.00%	OFF	No-Generic			
TRAZODONE (ORAL)	28.10%	ON	Yes-Generic			
MIRTAZAPINE (ORAL)	12.10%	ON	Yes-Generic			
MARPLAN (ORAL)	0.00%	ON	Yes			
VENLAFAXINE ER CAPSULES (ORAL)	5.10%	ON	Yes-Generic			
BUPROPION SR (ORAL)	14.40%	ON	Yes-Generic			
NEFAZODONE (ORAL)	0.20%	OFF	No-Generic			
BUPROPION (ORAL)	2.00%	ON	Yes-Generic			
VENLAFAXINE (ORAL)	3.40%	ON	Yes-Generic			
BUPROPION XL (ORAL)	1.80%	ON	Yes-Generic			
MIRTAZAPINE ODT (ORAL)	0.30%	ON	Yes-Generic			

NARDIL (ORAL)	0.00%	ON	Yes			
PHENELZINE (ORAL)	0.00%	OFF	Yes-Generic			
OLEPTRO ER (ORAL)	0.00%	OFF	No			
VIIBRYD TAB DS PK (ORAL)	0.00%	OFF	No			
VIIBRYD (ORAL)	0.80%	OFF	No			
PRISTIQ (ORAL)	1.60%	OFF	No			
VENLAFAXINE ER TABLETS (GENERIC) (ORAL)	0.00%	OFF	No-Generic			
VENLAFAXINE ER TABLETS (SCHWARZ) (ORAL)	0.10%	OFF	No-Generic			
TRANLYCYPROMINE SULFATE (ORAL)	0.00%	ON	Yes-Generic			
APLENZIN (ORAL)	0.00%	OFF	No			
EMSAM (TRANSDERMAL)	0.00%	OFF	No			

- Discussion:
- Kevin Izard questioned if we could control Cymbalta via a diagnosis code and only allow for specific codes.
- Rick Pope commented that rebates for Cymbalta are tied to not having a diagnosis restriction.
- Pat Towers requested to get a Cymbalta report for the next meeting in May to see how the utilization has changed. Rachel Currans-Henry stated we could do this by making assumptions on why the drug was used. Pat Towers withdrew her request for the report.
- Ronald Diamond stated that Cymbalta would be preferred in this class as well, because it is preferred in neuropathic pain. Rebates are tied to not having diagnosis restrictions, so Cymbalta would most likely not offer a rebate if there was a diagnosis restriction placed on it. Ronald stated that once Cymbalta goes preferred, we will lose control of it.
- Rachel Currans-Henry pointed out to the committee that based on last year's recommendations, a few brands were preferred over generics, as the summer progressed, Wellbutrin XL and Effexor XR which were preferred over generics were no longer cost effective and we changed back to the generics being preferred.
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second –Catherine Decker
 - The vote was 8-1 in favor of the motion. Steve Maike was opposed to the motion.
 - Motion passes

ANTIDEPRESSANTS, SSRI's						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
FLUOXETINE TABLET (ORAL)	3.40%	ON	Yes-Generic			
CITALOPRAM TABLET (ORAL)	27.90%	ON	Yes-Generic			
SERTRALINE TABLET (ORAL)	29.90%	ON	Yes-Generic			
FLUOXETINE CAPSULE (ORAL)	22.10%	ON	Yes-Generic			
FLUOXETINE SOLUTION	0.40%	ON	Yes-Generic			

(ORAL)						
PAROXETINE TABLET (ORAL)	10.00%	ON	Yes-Generic			
FLUVOXAMINE (ORAL)	0.70%	ON	Yes-Generic			
FLUOXETINE 60 MG (ORAL)	0.00%	ON	Yes-Generic			
CITALOPRAM SOLUTION (ORAL)	0.10%	ON	Yes-Generic			
LEXAPRO SOLUTION (ORAL)	0.00%	OFF	No			
LEXAPRO TABLET (ORAL)	1.80%	OFF	No			
PEXEVA (ORAL)	0.00%	OFF	No			
SERTRALINE CONC (ORAL)	0.10%	ON	Yes-Generic			
LUVOX CR (ORAL)	0.00%	OFF	No			
ESCITALOPRAM SOLUTION (ORAL)	0.00%	OFF	No-Generic			
ESCITALOPRAM TABLET (ORAL)	3.30%	OFF	No-Generic			
PAROXETINE CR (ORAL)	0.10%	OFF	No-Generic			
FLUOXETINE CAPSULE DR (ORAL)	0.00%	OFF	No-Generic			
PAXIL SUSPENSION (ORAL)	0.00%	ON	Yes			

- Discussion:
- Rachel Currans-Henry pointed out to the Committee that during the Mental Health Drug Advisor’s Group last meeting, it was suggested to monitor the cost of generic Lexapro and make it preferred once the price is lower and comparable to the other generics. Rachel also stated we will monitor escitalopram and make possible future changes.
- Steve Maike stated that we should watch the total market share of the class as Cymbalta is now preferred.
- Ronald Diamond made a motion to accept staff recommendations as presented.
 - Second –Pat Towers
 - All members were in favor of this motion.
 - Motion passes

ANTIPARKINSON'S AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BENZTROPINE (ORAL)	32.60%	ON	Yes-Generic			
PRAMIPEXOLE (ORAL)	11.10%	ON	Yes-Generic			
ROPINIROLE (ORAL)	28.70%	ON	Yes-Generic			

TRIHEXYPHENIDYL TABLET (ORAL)	5.40%	ON	Yes-Generic			
TRIHEXYPHENIDYL ELIXIR (ORAL)	0.30%	ON	Yes-Generic			
CARBIDOPA / LEVODOPA (ORAL)	15.70%	ON	Yes-Generic			
CARBIDOPA / LEVODOPA ER (ORAL)	3.40%	ON	Yes-Generic			
SELEGILINE TABLET (ORAL)	0.10%	ON	Yes-Generic			
SELEGILINE CAPSULE (ORAL)	0.20%	ON	Yes-Generic			
ZELAPAR (ORAL)	0.00%	OFF	No			
CARBIDOPA / LEVODOPA ODT (ORAL)	0.10%	ON	Yes-Generic			
NEUPRO (TRANSDERM)	0.00%	OFF	No			
TASMAR (ORAL)	0.00%	OFF	No			
BROMOCRIPTINE (ORAL)	1.00%	ON	Yes-Generic			
AZILECT (ORAL)	0.30%	OFF	No			
ROPINIROLE ER (ORAL)	0.10%	OFF	No-Generic			
STALEVO (ORAL)	0.50%	ON	Yes			
COMTAN (ORAL)	0.20%	OFF	No			
REQUIP XL (ORAL)	0.10%	OFF	No			
MIRAPEX ER (ORAL)	0.00%	OFF	No			
CARBIDOPA/LEVODOPA/ENTACAPONE (ORAL)	0.00%	OFF	No-Generic			
ENTACAPONE (ORAL)	0.00%	OFF	No-Generic			
PARCOPA (ORAL)	0.00%	OFF	No-Generic			

- Discussion:
- Rachel Currans-Henry pointed out to the committee that the Mental Health Drug Advisors Group had no comments on this class.
- James Boblin questioned why the psychiatrists are even looking at this class.
- James Boblin made a motion to accept staff recommendations as presented.
 - Second –Al Liegel
 - All members were in favor of this motion.
 - Motion passes

ANTIPSYCHOTICS

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
OLANZAPINE TABLET (ORAL)	4.90%	OFF	Yes-Generic			
FLUPHENAZINE TABLET (ORAL)	0.90%	ON	Yes-Generic			
RISPERIDONE TABLET (ORAL)	26.20%	ON	Yes-Generic			
HALOPERIDOL LACTATE CONC (ORAL)	0.10%	ON	Yes-Generic			
THIOTHIXENE (ORAL)	0.50%	ON	Yes-Generic			
HALOPERIDOL (ORAL)	3.60%	ON	Yes-Generic			
THIORIDAZINE (ORAL)	0.20%	OFF	No-Generic			
QUETIAPINE TABLETS (ORAL)	25.20%	ON	Yes-Generic			
TRIFLUOPERAZINE (ORAL)	0.20%	ON	Yes-Generic			
ORAP (ORAL)	0.10%	ON	Yes			
LOXAPINE (ORAL)	0.50%	NA	Yes-Generic			
AMITRIPTYLINE / PERPHENAZINE (ORAL)	0.10%	ON	Yes-Generic			
FLUPHENAZINE ELIXIR/SOLN (ORAL)	0.00%	ON	Yes-Generic			
RISPERIDONE SOLUTION (ORAL)	0.90%	ON	Yes-Generic			
PERPHENAZINE (ORAL)	0.40%	ON	Yes-Generic			
FANAPT TITRATION PACK (ORAL)	0.00%	OFF	No			
CHLORPROMAZINE (ORAL)	0.70%	ON	Yes-Generic			
CLOZAPINE (ORAL)	3.00%	ON	Yes-Generic			
LATUDA (ORAL)	0.70%	OFF	No			
FANAPT TABLET (ORAL)	0.20%	OFF	No			
RISPERIDONE ODT (ORAL)	0.80%	ON	Yes-Generic			
SAPHRIS (SUBLINGUAL)	0.40%	OFF	No			
SEROQUEL XR (ORAL)	1.30%	OFF	No			
ABILIFY TABLET (ORAL)	15.60%	OFF	No			
ZIPRASIDONE CAPSULE (ORAL)	0.30%	ON	Yes-Generic			
FAZACLO (ORAL)	0.20%	OFF	No			
ABILIFY DISCMELT (ORAL)	0.00%	OFF	No			
INVEGA (ORAL)	1.10%	OFF	No			
OLANZAPINE/FLUOXETINE (ORAL)	0.00%	OFF	No-Generic			
ZYPREXA ZYDIS (ORAL)	0.20%	OFF	No			
ABILIFY SOLUTION (ORAL)	0.10%	OFF	No			
OLANZAPINE ODT (ORAL)	0.50%	OFF	No-Generic			

SYMBYAX (ORAL)	0.10%	OFF	No			
----------------	-------	-----	----	--	--	--

- Discussion:
- Rachel Currans-Henry asked if with multiple generics now available, would there be any interest in requiring members to fail on two preferred drugs, before being eligible to go to a non-preferred? There was both positive and negative feedback from the Mental Health Drug Advisors Group and Committee members.
- Brett Davis stated that this policy consideration has been discussed extensively amongst DHS staff and with the Department’s Mental Health Advisors. Extensive consideration has been given to both financial and member impacts if this policy were implemented.
- Rachel Currans-Henry clarified that today’s staff recommendation does not include requiring two generic trials to get to a non-preferred drug.
- James Boblin questioned to the committee, in the average person starting on an antipsychotic, how long does each trial of a drug last? And would having to try two generics tie your hands? Ronald Diamond responded by stating that it could be a week or two, but it depends on the drugs and the patient. Also, a week or two for the first drug, but if you are on the third or fourth drug, trials may need to last a few months.
- James Boblin stated that consumers will always request the most open access to formularies, as was the case with the anti-epileptic drugs, but we have managed to use the PDL effectively for those drugs. Wouldn’t that be the same for anti-psychotics?
- Steve Maike stated that there are numerous generics that last year were only available as brand, and now that they are generic, members don’t see them as good enough.
- Pat Towers stated that there are a couple of new drugs that seem to show promise, next year we should be able to have a better idea of where to place them.
- Ronald Diamond questioned that if we take the rebate, based on cost only, would it not make sense to take Abilify? He also stated that there is not enough data now about the new agents to evaluate based on metabolic side effects.
- Rick Pope stated that if Abilify was available with open access, it would not be cost neutral, it would increase costs.

- Ronald Diamond made a motion to accept staff recommendations as presented.
 - Second –James Boblin
 - All members were in favor of this motion.
 - Motion passes

SEDATIVE HYPNOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ZOLPIDEM (ORAL)	68.40%	ON	Yes-Generic			
TEMAZEPAM (ORAL)	21.20%	ON	Yes-Generic			
FLURAZEPAM (ORAL)	0.30%	OFF	No-Generic			
TRIAZOLAM (ORAL)	0.60%	OFF	No-Generic			
DORAL (ORAL)	0.00%	OFF	No			
ZALEPLON (ORAL)	1.40%	ON	Yes-Generic			
ESTAZOLAM (ORAL)	0.70%	ON	Yes-Generic			
CHLORAL HYDRATE SYRUP (ORAL)	0.10%	ON	Yes-Generic			
INTERMEZZO (SUBLINGUAL)	0.00%	OFF	No			

LUNESTA (ORAL)	2.80%	OFF	No			
SOMNOTE (ORAL)	0.10%	OFF	No-Generic			
ZOLPIMIST (ORAL)	0.00%	OFF	No			
ROZEREM (ORAL)	1.60%	ON	Yes			
EDLUAR (SUBLINGUAL)	0.00%	OFF	No			
SILENOR (ORAL)	0.00%	OFF	No			
ZOLPIDEM ER (ORAL)	2.80%	OFF	No-Generic			
TEMAZEPAM 7.5 MG (ORAL)	0.10%	OFF	No-Generic			
TEMAZEPAM 22.5 MG (ORAL)	0.00%	OFF	No-Generic			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second –Kevin Izard
 - All members were in favor of this motion.
 - Motion passes

STIMULANTS AND RELATED AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
METHYLPHENIDATE (ORAL)	7.20%	ON	Yes-Generic			
DEXTROAMPHETAMINE TABLET (ORAL)	0.70%	ON	Yes-Generic			
PROVIGIL (ORAL)	0.10%	OFF	No			
ADDERALL (ORAL)	0.10%	ON	Yes			
METHYLPHENIDATE ER (ORAL)	1.80%	ON	Yes-Generic			
FOCALIN XR (ORAL)	4.60%	ON	Yes			
METADATE CD (ORAL)	2.10%	ON	Yes			
DEXMETHYLPHENIDATE (ORAL)	1.10%	ON	Yes-Generic			
VYVANSE (ORAL)	15.20%	ON	Yes			
DEXEDRINE SPANSULE (ORAL)	0.00%	ON	Yes			
AMPHETAMINE SALT COMBO (ORAL)	17.10%	ON	Yes-Generic			
RITALIN LA (ORAL)	0.20%	OFF	No			
RITALIN LA 10 MG CAPSULE (ORAL)	0.10%	OFF	No			
ADDERALL XR (ORAL)	25.50%	ON	Yes			
STRATTERA (ORAL)	3.40%	OFF	Yes			
DAYTRANA (TRANSDERMAL)	0.90%	ON	Yes			

METHYLPHENIDATE ER (CONCERTA) (ORAL)	0.20%	OFF	Yes-Generic			
DESOXYN (ORAL)	0.00%	OFF	No			
INTUNIV (ORAL)	3.00%	OFF	Yes			
PROCENTRA (ORAL)	0.00%	OFF	No			
METHYLIN CHEWABLE TABLETS (ORAL)	0.00%	ON	Yes			
AMPHETAMINE SALT COMBO ER (TEVA, GLOBAL) (ORAL)	0.80%	OFF	No-Generic			
METHYLPHENIDATE ER (GEN RITALIN LA) (ORAL)	0.10%	OFF	No-Generic			
KAPVAY (ORAL)	0.30%	OFF	No			
METHYLIN SOLUTION (ORAL)	0.00%	OFF	No			
NUVIGIL (ORAL)	0.00%	OFF	No			
METHYLPHENIDATE CD (ORAL)	0.00%	OFF	No-Generic			
AMPHETAMINE SALT COMBO ER (ORAL)	0.00%	OFF	No-Generic			
CONCERTA (ORAL)	13.60 %	ON	Yes			
DEXTROAMPHETAMINE CAPSULE ER (ORAL)	1.40%	ON	Yes-Generic			
MODAFINIL (ORAL)	0.20%	OFF	No-Generic			
METHYLPHENIDATE SOLUTION (ORAL)	0.00%	OFF	No-Generic			
METHAMPHETAMINE (ORAL)	0.00%	OFF	No-Generic			

- Discussion:
- Rachel Currans-Henry pointed out to the committee that because of shortages, we continue to prefer both brands and their generic equivalents for some drugs, to ensure we have sufficient availability for members.
- Ron Diamond questioned why Strattera is being recommended as a preferred drug. It is not as effective as traditional stimulants. Considering cost, there are less expensive generic products such as bupropion, guanfacine that could be used.
- Kevin Izard questioned what is wrong with preferring Strattera and what is the issue with the drug? You can give more refills with Strattera as it is not a controlled substance. He mentioned having a patient with chronic pain, and didn't want to give him another controlled substance. Strattera would have been a prescribing option, if it had been available without prior authorization.
- Rick Pope stated that Strattera is more likely to be utilized with new starts than with members already taking a stimulant product.
- Al Liegel questioned when Strattera will go generic.
- Rick Pope stated that most likely late 2014.

- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second –Rosanne Barber
 - The vote was 6-3 in favor of the motion. Steve Maike, Ronald Diamond and Al Liegel were opposed to the motion.
 - Motion passes

ANTIPSORIATICS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DOVONEX CREAM (TOPICAL)	45.20%	NR	Yes			
VECTICAL (TOPICAL)	1.30%	NR	No			
CALCIPOTRIENE SOLUTION (TOPICAL)	8.50%	NR	Yes-Generic			
TACLONEX SCALP (TOPICAL)	3.60%	NR	No			
CALCIPOTRIENE OINTMENT (TOPICAL)	18.50%	NR	Yes-Generic			
TACLONEX OINTMENT (TOPICAL)	20.80%	NR	No			
CALCITRIOL OINTMENT (TOPICAL)	1.50%	NR	No-Generic			
CALCITRENE (TOPICAL)	0.50%	NR	No-Generic			
CALCIPOTRIENE CREAM (TOPICAL)	0.00%	NR	No-Generic			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second –Kevin Izard
 - All members were in favor of this motion.
 - Motion passes